Astellas Gene Therapies Press Release – Clinical Trial Update

June 28, 2022

“On June 26, 2022, Astellas Pharma, Inc. (“Astellas”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 clinical trial evaluating AT845 (“the investigational gene therapy candidate”) in patients with Late Onset Pompe Disease (LOPD). The hold was placed following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants.” – Weston Miller, MD (Senior Medical Director, Clinical Development) and Hilary D’Anna (Senior Manager, Patient Advocacy & Engagement)

Click here to read the press release.

OTHER NEWS

2022 PCMA Pull for Pompe Fundraiser

The AMDA is excited to announce that the 11th Annual PCMA’s Pull for Pompe will take place on Saturday, April 30, 2022 at the National Shooting Complex in San Antonio, Texas! The Pull for Pompe clay shooting event is designed for all ages and ability levels. Please...

read more

10th Annual PCMA Pull for Pompe!

The AMDA is excited to announce that the 10th Annual PCMA’s Pull for Pompe will take place on Saturday, April 4, 2020 at the National Shooting Complex in San Antonio, Texas! The Pull for Pompe clay shooting event is designed for all ages and ability levels. Please...

read more

 Acid Maltase Deficiency Association

GET INVOLVED

Your generous contribution will go a long way into improving the quality of life of Pompe Disease Patients worldwide. Donations go towards Pompe Disease Research.

If you are interested in learning more about Pompe Disease and would like to make a contribution in support of necessary research, please contact us at:

(210) 494-6144

info@amda-pompe.org

AMDA

PO Box 700248

San Antonio, Texas 78270 USA